Posts tagged Phase 2 development
Ladenburg up Novavax to buy

Ladenburg Thalmann upgraded Novavax (NASDAQ:NVAX) to “buy” from “neutral” with a new price target of $1.60 after the company presented encouraging preclinical data from its nanoparticle influenza vaccine, NanoFlu, and outlined a clinical development strategy targeting older adults. The stock closed at 97 cents on Aug. 8.

Read More
Ladenburg starts AIT Therapeutics at buy

Ladenburg Thalmann launched coverage of AIT Therapeutics (NASDAQ:AITB) with a “buy” rating and $17 price target. The stock closed at $5.50 on Aug. 4.

Read More
Ladenburg starts Albireo Pharma at buy

Ladenburg Thalmann initiated coverage of Albireo Pharma (NASDAQ:ALBO) with a “buy” rating and $40 price target. The stock closed at $20.28 on Feb. 15.

Read More
HCW starts Cidara Therapeutics at buy

H.C. Wainwright launched coverage of Cidara Therapeutics (NASDAQ:CDTX) with a “buy” rating and $25 price target. The stock closed at $10.80 on Dec. 16.

Read More